Kidney protection: A key target in the management of patients with diabetes

Journal of Hypertension

Volumn 27, Issue SUPPL. 1, 2009, Pages

  Ruilope, Luis M ^a   Segura, Julian ^a  

^a HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

Author keywords

Diabetic nephropathy; Perindopril indapamide combination; Renal protection; Type 2 diabetes

Indexed keywords

ALBUMIN; GLICLAZIDE; INDAPAMIDE PLUS PERINDOPRIL; PLACEBO;

BLOOD PRESSURE REGULATION; CARDIOVASCULAR RISK; CLINICAL TRIAL; DIABETIC NEPHROPATHY; DISEASE COURSE; HUMAN; HYPERTENSION; IMPAIRED GLUCOSE TOLERANCE; MICROALBUMINURIA; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROGNOSIS; RENAL PROTECTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SYSTOLIC BLOOD PRESSURE; URINARY EXCRETION; ARTICLE; DIABETES MELLITUS; KIDNEY DISEASE; PATHOPHYSIOLOGY;

DIABETES COMPLICATIONS; DIABETES MELLITUS; HUMANS; KIDNEY DISEASES;

EID: 68049143088     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.hjh.0000354419.15934.84     Document Type: Review

References (15)

1. Foley R, Collins AJ. End-stage renal disease in the United States: an update from the United States Renal Data System. J Am Soc Nephrol 2007; 18:2644-2648.
2. Segura J, Zanchetti A, Ruilope LM. On the need of estimating renal function for cardiovascular risk assessment. J Hypertens 2004; 22:1635-1639.
3. Dzau VJ, Antman EM, Black HR, Hayes DL, Manson JE, Plutzky J, et al. The cardiovascular disease continuum validated: clinical evidence of improved patient outcomes. Part I: Pathophysiology and clinical trial evidence (risk factors through stable coronary artery disease). Circulation 2006; 114:2850-2870. (Pubitemid 46018288)
4. Ritz E, Orth SR. Nephropathy in patients with type 2 diabetes mellitus. N Engl J Med 1999; 341:1127-1133.
5. Knobler H, Zornitzki T, Vered S, Oettinger M, Levy R, Caspi A, et al. Reduced glomerular filtration rate in asymptomatic diabetic patients: predictor of increased risk for cardiac events independent of albuminuria. J Am Coll Cardiol 2004; 44:2142-2148.
6. Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, et al. 2007 Guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007; 25:1105-1187. (Pubitemid 46924065)
7. Chalmers J. Efficacy and acceptability of the fixed low-dose perindopril-indapamide combination as first-line therapy in hypertension. Eur Heart J 1999; I Suppl. L: L20-L25.
8. Ruggenenti P, Fassi A, Ilieva AP, Bruno S, Iliev IP, Brusegan V, et al. Preventing microalbuminuria in type 2 diabetes. N Engl J Med 2004; 351:1941-1951.
9. ADVANCE Collaborative Group. Effects of a fixed combination of perindopril and indapamideon macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE Trial): a randomised controlled trial. Lancet 2007; 370:829-840.
10. De Galan BE, Perkovic V, Ninomiya T, Pillai A, Patel A, Cass A, et al. Lowering blood pressure reduced renal events in type 2 diabetes. J Am Soc Nephrol 2009; 20:883-892.
11. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345:851-860.
12. Parving HH, Lehnert H, Brochner-Mortensen J, Gomis R, Andersen S, Arner P. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001; 345:870-878. (Pubitemid 34940826)
13. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345:861-869. (Pubitemid 34940825)
14. ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008; 358:2560-2572.
15. Perkovic V, Ninomiya T, de Galan BE, Zoungas S, Cass A, et al. Joint effects of routine blood pressure lowering and intensive glucose control in the ADVANCE Trial. Clin J Am Soc Nephrol 2008; 3:RB01-RB04.